Back to top
more

Insulet (PODD)

(Delayed Data from NSDQ)

$235.43 USD

235.43
607,131

-3.37 (-1.41%)

Updated Sep 26, 2024 04:00 PM ET

After-Market: $235.71 +0.28 (0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (61 out of 252)

Industry: Medical - Products

Better trading starts here.

Zacks News

Quest Diagnostics' (DGX) New Pact to Scale Precision Medicine

Quest Diagnostics' (DGX) will supply next-generation sequencing and enhanced RNA extraction services for Scipher's PrismRA test through a new collaboration.

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Accelerate Diagnostics (AXDX) Expands in In Vitro Diagnostics

Accelerate Diagnostics' (AXDX) Arc system eliminates the need for overnight culture incubation, drastically reducing the wait time for identification results.

Charles River (CRL) Backs the Quest to Cure SPG56 via New Deal

Charles River (CRL) and GC4K announce a gene therapy manufacturing collaboration.

Smith & Nephew (SNN) New Buyout Expands Sports Medicine Suite

Smith & Nephew (SNN) will pay an initial cash consideration of $180 million at closure, with an additional $150 million based on financial performance to acquire CartiHeal.

Penumbra's (PEN) Expansion Moves, New Launches Aid Growth

Penumbra (PEN) expects to materially increase both revenues and profitability of the international business in the next three years and beyond.

Here's Why You Should Retain Teleflex (TFX) Stock for Now

Investors remain optimistic about Teleflex (TFX) on the strength of the Vascular and Interventional businesses.

3 Reasons Why Growth Investors Shouldn't Overlook Insulet (PODD)

Insulet (PODD) possesses solid growth attributes, which could help it handily outperform the market.

Here's Why Investors Should Retain Labcorp (LH) Stock for Now

Investors are increasingly optimistic about Labcorp (LH) due to development in targeted high-growth areas.

Orthofix (OFIX) Q3 Earnings Top Estimates, 2023 Sales View Cut

Orthofix (OFIX) saw very strong growth across multiple business segments and product lines in Q3.

Labcorp (LH) Closes the Legacy Health Asset Acquisition Deal

Labcorp (LH) finalizes the comprehensive laboratory relationship with Legacy Health.

Insulet (PODD) Up 31.5% Since Q3 Earnings: What's Driving It?

Insulet (PODD) continues to gain from the strong adoption of Ommipod 5 and market expansion.

This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.

EssilorLuxottica (ESLOY), Moncler Ink Luxury Eyewear Deal

The first Moncler Lunettes collection produced with EssilorLuxottica (ESLOY) is called Fall-Winter 2024.

If You Invested $1000 in Insulet a Decade Ago, This is How Much It'd Be Worth Now

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Here's Why You Should Retain Edward Lifesciences (EW) Stock Now

Investors remain optimistic about Edward Lifesciences (EW) due to Surgical's differentiated portfolio and TMTT franchise.

Quest Diagnostics' (DGX) New Pact to Advance Cancer Screening

Quest Diagnostics' (DGX) latest partnership will increase the likelihood that Americans will eventually have an easy, reliable and accessible way to check for colorectal cancer.

Abbott (ABT) Benefits From Innovation Amid FX Headwinds

Abbott's (ABT) mAbxience collaboration is likely to help introduce cutting-edge medicines in the areas of oncology, women's health and respiratory diseases.

Teleflex (TFX) Enrolls First Patient in ACCESS-MANTA Registry

Teleflex's (TFX) ACCESS-MANTA Registry is likely to examine the contemporary on-label use of the MANTA VCD.

Medtronic (MDT) Q2 Earnings Beat Estimates, 2024 View Up

Medtronic (MDT) Q2 results reflect broad strength across businesses and geographies, benefiting from durable fundamentals.

Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now

Investors are optimistic about Myriad Genetics (MYGN) on recent partnerships and growth in testing volumes.

Zimmer Biomet's (ZBH) Knee Sales Robust, Macro Woes Hurt

Zimmer Biomet (ZBH) is working to strengthen its foothold in emerging markets that provide long-term opportunities for growth.

Boston Scientific (BSX) Closes the Relievant Medsystems Buyout

Boston Scientific (BSX) expands the neuromodulation portfolio with the acquisition of Relievant Medsystems.

Here's Why Investors Should Retain STERIS (STE) Stock for Now

STERIS' (STE) Healthcare segment continues to benefit from procedure volume recovery.

National Vision's (EYE) Market Expansion Aids, Inflation Ails

National Vision (EYE) is expanding sales by the continued rollout of its remote medicine technology.